Home Online Features Stealth BioTherapeutics Announces Achievement of 50% Enrollment Target in Phase 3 ReNEW Study of Elamipretide in Patients with Dry Age-Related Macular Degeneration
Stealth BioTherapeutics Announces Achievement of 50% Enrollment Target in Phase 3 ReNEW Study of Elamipretide in Patients with Dry Age-Related Macular Degeneration
Hand-out
Press Releases
STEALTH BIOTHERAPEUTICS INC.  
March 13, 2025

Stealth BioTherapeutics Announces Achievement of 50% Enrollment Target in Phase 3 ReNEW Study of Elamipretide in Patients with Dry Age-Related Macular Degeneration

NEEDHAM, Mass., March 13, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for diseases

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social